This article was originally published in The Gray Sheet
Executive SummarySale of $25 mil. in zero coupon convertible debentures to an existing institutional investor under an agreement announced June 29 brings total cash on hand to approximately $98 mil. This "should allow us to continue investing in our telomerase drug discovery, stem cell and nuclear transfer development programs," Geron explains. The Menlo Park, California firm stem cell R&D is focused on discovering, developing and commercializing therapeutic and diagnostic products for applications in oncology, research tools for drug discovery and regenerative medicine
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.